Circulation. 2002;106:2224-2230
Published online before print October 7, 2002, doi: 10.1161/01.CIR.0000035655.45453.D2
Published online before print October 7, 2002, doi: 10.1161/01.CIR.0000035655.45453.D2
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:2224.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic Valvular Lesions and in Human Plasma
From the Division of Cardiology, University of Washington, Seattle.
Correspondence to Kevin D. O’Brien, MD, Division of Cardiology, Box 356422, University of Washington, 1959 N.E. Pacific St, Seattle, WA 98195-6422. E-mail cardiac{at}u.washington.edu
Background— Recent studies have demonstrated that lesions of aortic sclerosis and stenosis share several similarities with lesions of atherosclerosis. In atherosclerosis, angiotensin-converting enzyme (ACE) is expressed by a subset of macrophages. This study was undertaken to determine whether ACE might be present in aortic sclerosis or stenosis lesions.
Methods and Results— Immunohistochemistry was performed on 26 paraffin-embedded human aortic valves. Monospecific antibodies were used to identify ACE, macrophages, angiotensin II type 1 receptor (AT-1 receptor), angiotensin II, and apolipoprotein B. Human low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were isolated from plasma of normal volunteers by sequential density-gradient ultracentrifugation. ACE was not present in normal valves but was present in all valves with aortic sclerosis or stenosis lesions. ACE was detected on a subset of lesion macrophages but was present primarily in an extracellular distribution, where it colocalized with apolipoprotein B. ACE was detected by Western blotting on plasma LDL but not on HDL isolated from normal volunteers. Angiotensin II, the enzymatic product of ACE, was colocalized with ACE in valve lesions. ACE also was colocalized with apolipoprotein B in an adjacent coronary atherosclerotic plaque.
Conclusions— ACE is present in aortic sclerosis and stenosis lesions, where it may participate in lesion development, as is evidenced by the presence of its enzymatic product, angiotensin II. The observation of an association of ACE with LDL in both lesions and plasma suggests that LDL may deliver ACE to lesions and has implications for the role of ACE-containing LDL in other diseases, such as atherosclerosis.
Key Words: angiotensin • apolipoproteins • immunohistochemistry • lipoproteins • valves
This article has been cited by other articles:
 |
|
 |
|
  2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, October 7, 2008; 118(15): e523 - e661. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dong, C. Zhang, J. B. Feng, Y. X. Zhao, S. Y. Li, Y. P. Yang, Q. L. Dong, B. P. Deng, L. Zhu, Q. T. Yu, et al. Overexpression of ACE2 Enhances Plaque Stability in a Rabbit Model of Atherosclerosis Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1270 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Owens, R. Katz, E. Johnson, D. M. Shavelle, J. L. Probstfield, J. Takasu, J. R. Crouse, J. J. Carr, R. Kronmal, M. J. Budoff, et al. Interaction of Age With Lipoproteins as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis Arch Intern Med, June 9, 2008; 168(11): 1200 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Bosse, P. Mathieu, and P. Pibarot Genomics: The Next Step to Elucidate the Etiology of Calcific Aortic Valve Stenosis J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1327 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mihaljevic, M. R. Sayeed, S. C. Stamou, and S. Paul Pathophysiology of Aortic Valve Disease Card. Surg. Adult, January 1, 2008; 3(2008): 825 - 840. [Full Text]
|
|
|
|
|
|
D. Mohty, P. Pibarot, J.-P. Despres, C. Cote, B. Arsenault, A. Cartier, P. Cosnay, C. Couture, and P. Mathieu Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients With Aortic Stenosis Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Liu, V. R. Joag, and A. I. Gotlieb The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve Pathobiology Am. J. Pathol., November 1, 2007; 171(5): 1407 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Stewart, A. Haw III, R. Lopez, T. O. McDonald, J. M. Callaghan, M. J. McConville, K. J. Moore, G. J. Howlett, and K. D. O'Brien Serum amyloid P colocalizes with apolipoproteins in human atheroma: functional implications J. Lipid Res., October 1, 2007; 48(10): 2162 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.J. Grande-Allen, N. Osman, M.L. Ballinger, H. Dadlani, S. Marasco, and P.J. Little Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease Cardiovasc Res, October 1, 2007; 76(1): 19 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster Insights Into Degenerative Aortic Valve Disease J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Helske, M. Laine, M. Kupari, J. Lommi, H. Turto, L. Nurmi, I. Tikkanen, K. Werkkala, K. A. Lindstedt, and P. T. Kovanen Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves Eur. Heart J., August 1, 2007; 28(15): 1894 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Arishiro, M. Hoshiga, N. Negoro, D. Jin, S. Takai, M. Miyazaki, T. Ishihara, and T. Hanafusa Angiotensin Receptor-1 Blocker Inhibits Atherosclerotic Changes and Endothelial Disruption of the Aortic Valve in Hypercholesterolemic Rabbits J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1482 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Kerwin, K. D. O'Brien, M. S. Ferguson, N. Polissar, T. S. Hatsukami, and C. Yuan Inflammation in Carotid Atherosclerotic Plaque: A Dynamic Contrast-enhanced MR Imaging Study Radiology, November 1, 2006; 241(2): 459 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): 598 - 675. [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien Pathogenesis of Calcific Aortic Valve Disease: A Disease Process Comes of Age (and a Good Deal More) Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1721 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Briand, I. Lemieux, J. G. Dumesnil, P. Mathieu, A. Cartier, J.-P. Despres, M. Arsenault, J. Couet, and P. Pibarot Metabolic Syndrome Negatively Influences Disease Progression and Prognosis in Aortic Stenosis J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2229 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Helske, S. Syvaranta, M. Kupari, J. Lappalainen, M. Laine, J. Lommi, H. Turto, M. Mayranpaa, K. Werkkala, P. T. Kovanen, et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves Eur. Heart J., June 2, 2006; 27(12): 1495 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Katz, N. D. Wong, R. Kronmal, J. Takasu, D. M. Shavelle, J. L. Probstfield, A. G. Bertoni, M. J. Budoff, and K. D. O'Brien Features of the Metabolic Syndrome and Diabetes Mellitus as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis Circulation, May 2, 2006; 113(17): 2113 - 2119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Allison, P. Cheung, M. H. Criqui, R. D. Langer, and C. M. Wright Mitral and Aortic Annular Calcification Are Highly Associated With Systemic Calcified Atherosclerosis Circulation, February 14, 2006; 113(6): 861 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Baumgartner Aortic stenosis: medical and surgical management Heart, November 1, 2005; 91(11): 1483 - 1488. [Full Text] [PDF]
|
|
|
|
|
|
D M Shavelle Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis? Heart, October 1, 2005; 91(10): 1257 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Jimenez-Candil, J Bermejo, R Yotti, C Cortina, M Moreno, J L Cantalapiedra, and M A Garcia-Fernandez Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study Heart, October 1, 2005; 91(10): 1311 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kupari, H. Turto, and J. Lommi Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur. Heart J., September 1, 2005; 26(17): 1790 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Fondard, D. Detaint, B. Iung, C. Choqueux, H. Adle-Biassette, M. Jarraya, U. Hvass, J.-P. Couetil, D. Henin, J.-B. Michel, et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors Eur. Heart J., July 1, 2005; 26(13): 1333 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Freeman and C. M. Otto Spectrum of Calcific Aortic Valve Disease: Pathogenesis, Disease Progression, and Treatment Strategies Circulation, June 21, 2005; 111(24): 3316 - 3326. [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien, J. L. Probstfield, M. T. Caulfield, K. Nasir, J. Takasu, D. M. Shavelle, A. H. Wu, X.-Q. Zhao, and M. J. Budoff Angiotensin-Converting Enzyme Inhibitors and Change in Aortic Valve Calcium Arch Intern Med, April 25, 2005; 165(8): 858 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien and D. P. Fishbein Mitral valve abnormalities in congestive heart failure: An interplay between form and function? J. Am. Coll. Cardiol., January 4, 2005; 45(1): 62 - 64. [Full Text] [PDF]
|
|
|
|
|
|
Systolic murmur in an asymptomatic 70 year old man Heart, January 1, 2005; 91(1): 125 - 125. [Full Text] [PDF]
|
|
|
|
|
|
S. Helske, K. A. Lindstedt, M. Laine, M. Mayranpaa, K. Werkkala, J. Lommi, H. Turto, M. Kupari, and P. T. Kovanen Induction of local angiotensin II-producing systems in stenotic aortic valves J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1859 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Rajamannan and C. M. Otto Targeted Therapy to Prevent Progression of Calcific Aortic Stenosis Circulation, September 7, 2004; 110(10): 1180 - 1182. [Full Text] [PDF]
|
|
|
|
|
|
R. Rosenhek, F. Rader, N. Loho, H. Gabriel, M. Heger, U. Klaar, M. Schemper, T. Binder, G. Maurer, and H. Baumgartner Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis Circulation, September 7, 2004; 110(10): 1291 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Otto Why is aortic sclerosis associated with adverse clinical outcomes? J. Am. Coll. Cardiol., January 21, 2004; 43(2): 176 - 178. [Full Text] [PDF]
|
|
|
|
|
|
K.-L. Chan Is aortic stenosis a preventable disease? J. Am. Coll. Cardiol., August 20, 2003; 42(4): 593 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Bashore and T. J. Gardner Valvular heart disease J. Am. Coll. Cardiol., July 16, 2003; 42(2): 388 - 390. [Full Text] [PDF]
|
|